Clinical trials: Nonfluent Aphasia, Progressive
Predicted Tauopathies, Including, Progressive Supranuclear Palsy
Davunetide (AL-108) in Predicted Tauopathies - Pilot Study
The primary objective of the study is to obtain preliminary safety and tolerability data with davunetide (NAP, AL-108) in patients with a tauopathy (frontotemporal lobar degeneration [FTLD] with predicted tau pathology…
- Conditions
- Predicted Tauopathies, Including, Progressive Supranuclear Palsy, Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17, Corticobasal Degeneration Syndrome
- Trial name
- NCT01056965
- Testing
- davunetide (AL-108, NAP)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of California, San Francisco
PPA, Primary Progressive Aphasia
PiB PET Scanning in Speech and Language Based Dementias
The study is designed to determine whether there are clinical features that can be used as biomarkers to predict whether underlying Alzheimer's pathology is the cause of a speech and language based dementia.
- Conditions
- PPA, Primary Progressive Aphasia, Aphasia, Non-fluent Aphasia
- Trial name
- NCT01623284
- Testing
- C-11 PiB, F-18 FDG
- Where
- United States
- Volunteers
- 168 people
- Sponsor
- Mayo Clinic
Primary Progressive Aphasia, Nonfluent Progressive Aphasia
Language Treatment for Progressive Aphasia
Progressive aphasia is characterized by a steady and progressive loss of language skills in the presence of relatively preserved memory, attention, and thinking.
- Conditions
- Primary Progressive Aphasia, Nonfluent Progressive Aphasia, Semantic Dementia
- Trial name
- NCT00957710
- Testing
- Errorless learning
- Where
- Canada
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Baycrest